TCM
KALV

Tang Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

Tang Capital Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$92.1M Hold
4,573,530
– – 4.68% 10
2025
Q4 		$73.9M Sell
4,573,530
-468,268
-9% -$6.2M 3.65% 10
2025
Q3 		$61.4M Buy
5,041,798
+100,000
+2% +$1.38M 2.36% 8
2025
Q2 		$55.9M Hold
4,941,798
– – 2.82% 7
2025
Q1 		$57M Buy
4,941,798
+47,951
+1% +$489K 3.16% 6
2024
Q4 		$41.5M Buy
4,893,847
+572,300
+13% +$5.93M 2.74% 8
2024
Q3 		$50M Buy
4,321,547
+102,718
+2% +$1.29M 3.57% 6
2024
Q2 		$49.7M Buy
4,218,829
+93,484
+2% +$1.09M 5.06% 3
2024
Q1 		$48.9M Buy
4,125,345
+685,000
+20% +$9.13M 5.09% 3
2023
Q4 		$42.1M Hold
3,440,345
– – 3.89% 4
2023
Q3 		$33.1M Buy
3,440,345
+788,952
+30% +$8.06M 4.67% 4
2023
Q2 		$23.9M Hold
2,651,393
– – 3.51% 7
2023
Q1 		$20.8M Sell
2,651,393
-545,053
-17% -$4.07M 3.11% 8
2022
Q4 		$21.6M Buy
3,196,446
+1,396,446
+78% +$7.48M 3.14% 10
2022
Q3 		$26.1M Hold
1,800,000
– – 3.2% 9
2022
Q2 		$17.7M Buy
1,800,000
+1,151,731
+178% +$12.7M 2.69% 11
2022
Q1 		$9.55M Buy
+648,269
New +$9.31M 1.91% 15

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Tang Capital Management's KALV Position: Q1 2026 in Review

Tang Capital Management held its KalVista Pharmaceuticals (KALV) position steady in Q1 2026 at 4,573,530 shares worth $92.1M. The position accounts for 4.68% of the portfolio, ranked #10.

Tang Capital Management first reported a position in KALV in Q1 2022 and has held it in 17 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Tang Capital Management held 4,573,530 shares of KalVista Pharmaceuticals worth $92.1M as of Q1 2026.
  • Tang Capital Management left its KalVista Pharmaceuticals share count unchanged in Q1 2026.
  • KalVista Pharmaceuticals made up 4.68% of Tang Capital Management's portfolio in Q1 2026, its #10 holding.
  • Tang Capital Management first reported a position in KalVista Pharmaceuticals in Q1 2022 and has held it in 17 quarters since.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Tang Capital Management's 13F filing for Q1 2026, filed 15 May 2026.